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Cancer Epidemiology: Shortcomings
and Possibilities
by Johannes Clemmesen*
The development of the concepts of initiators and promotors in carcinogenesis necessitates delib-
erations of evidence from human cancer epidemiology.
Recent arguments in favor of mortality data as a more reliable indicator of trends in cancer inci-
dence than morbidity data collected from cancer registries are disputed. Inconsistency in the use of
data is pointed out. Comparisons of data from cancer registration in Denmark with those from Con-
necticut and upstate New York show such congruity that it is impossible to accept suggestions of
systematic bias of significance without direct evidence to that effect.
Since accurate information on periods of exposure and on the onset of disease is fundamental to
considerations of initiators and promoters the following proposals are made. Payrolls or similar
data should be kept safe for 40 years for occupations where exposure to carcinogens may be sus-
pected. Experience on latent periods from the last 100 years should be systematically reassured.
Death certificates showing a diagnosis of malignant neoplasia should always state the histological
diagnosis if any.
Modernization of international cancer epidemiol-
ogy dates from 1946, when an international sympo-
sium held in Copenhagen recommended to the In-
terim Commission for a World Health Organization
that each country should have a cancer registry (1,
2). By a series of subsequent symposia held in Ox-
ford (1950), Louvain (1952), Kampala and Leopold-
ville (1956), Copenhagen (1958), London (1958), Tokyo
(1960) and Cairo (1961), sponsored by the Interna-
tional Union against Cancer, we succeeded in turn-
ing attention to the advantages of cancer regis-
tration in epidemiology.
Today some 60 cancer registries function all over
the world and as a result of the collection of ac-
curate data, cancer epidemiology has changed its
"Cinderella" existence in the backrooms of Public
Health offices into a university life, indulging in dis-
cussions of its subdivisions, aims and philosophy.
Cancer registries have contributed both to preven-
tion studies and to carcinogenesis research (3), and
although only a few of them cover sufficient years
to verify trends in cancer morbidity, the time will
soon come for many more.
Now the inspiring discussion around initiation
and promotion of carcinogenesis is presenting its
demands to epidemiology, and since recent reviews
The Danish Cancer Registry, Strandboulevard 49, Copen-
hagen 2100, Denmark
by Maclure and MacMahon (4) and by Doll and Peto
(5) have confirmed that epidemiology at present is
in no position to meet such demands, it will be our
task to examine the reasons why, and point to ways
to improve the instruments of cancer epidemiology.
In the first part of a voluminous report to the
U.S. Congress (5) Doll and Peto have attempted to
estimate the avoidable amount of cancer by compar-
ing morbidity rates from cancer registries all over
the world for those 50% of cancer patients aged be-
tween 34 and 64 years. Rates appear as taken by
their face values from low-risk and high-risk areas,
but without documentation of the quality of diagnos-
tics in various places. In the last part of the review,
however, the authors prefer mortality data as more
reliable than morbidity data for verifying trends in
cancer morbidity.
Accepting mortality data a priori as the more re-
liable source of information, they interprete devia-
tions from the rates from the oldest registries in
the United States-those for Connecticut and for
the State of New York less New York City-in dis-
favor of the registries, and of incidence data in
general.
Epidemiology Trends
Before evaluating this discrepancy, however, it is
only fair to point out that according to the two re-J. CLEMMESEN
views mentioned, cancer epidemiology at present
tends to follow different lines, sometimes inter-
twined in the same publication. The line favored by
the reviews is colloquially termed "black box epi-
demiology"-not any macabre allusion to those mor-
tality data which appear its favorite basis, but indi-
cating some trend to containment of information on
the mechanism of carcinogenesis, which some find
of less immediate interest to epidemiology as they
see it.
In contrast we find the authors referring to the
epidemiology of "pure scientists," but since the
whole discipline after all is medical, and thus ap-
plied science, it may be more adequate to distin-
guish between administration epidemiology (or
perhaps PR Epidemiology) and research epidemiol-
ogy or "scientific" or "critical" epidemiology (Table
1).
The first, orginal line of epidemiology is largely
represented today by discussions of administrative
or slightly political character, often addressing ad-
ministrators or the lay public through mass media.
Such reviews usually have to avoid complicated sci-
entific problems or details. In their context, "can-
cer" often figures as a single disease entity, and a
percent of the cancer total will often suffice, often
covering the two sexes together, for an entire coun-
try. Here the number of persons "killed by cancer"
will be of more immediate interest than the number
of patients, and consequently the significant differ-
Table 1. Comparison of features in
"administration epidemiology" and "research epidemiology."
Administration Research epidemiology
epidemiology (epidemiology, docu-
(black-box epidemiology, menting epidemiology)
PR epidemiology, sug-
gestive epidemiology)
Staffing Committees Experienced
researchers
Sources Reviews Checked
specified data
Data Mortality (percent, both Morbidity registration,
sexes) specific by sex, age,
site, histology
Scattergrams, simple Scattergrams
(correlation increased
with specification)
Terms "Good" evidence, Suggestive evidence,
carcinogenic conclusive evidence,
carcinopotency spe-
cified by species,
mutagenic
Results Opinions, hypotheses, Specified data,
suggestions, recom- exclusions, conclu-
mendations, sions, statements
reviews
ence between morbidity and mortality data may be
disregarded when convenient.
In contrast, the critical, scientific approach will
have to base its analyses on data as accurate as pos-
sible, specified by race, sex, age and site and veri-
fied by histology, from biopsy or autopsy. There-
fore, its workers often may have to refer to original
publications more detailed than the useful review
tables such as in "Cancer in Five Continents" (6-8).
Also the use of scattergrams is characteristic of
the two lines: (1) simple scattergrams plotting can-
cer incidence or mortality rates for various coun-
tries against national consumption of some or other
factor suspected of carcinogenicity, and (2) a similar
plotting allowing for some latent period and show-
ing the correlation to be closer after specification of
the suspect factor like substituting tobacco with cig-
arettes.
It seems obvious which method will be preferable
to "those whose scholarly austerity is unbending,"
and which will appeal to public press, and politi-
cians, less favorable to doubts and to qualifications
of attitudes to carcinogens. However our present
question is how to make any progress with the
black box, if Doll and Peto are correct that mortal-
ity data are more reliable than morbidity rates.
Mortality and Morbidity Data
In comparing mortality and morbidity data it is
fundamental that mortality is a function of morbid-
ity and therapy. Equally fundamental is that mortal-
ity and morbidity as given for the same year refer
to cases originating in different years. A neoplasm
of decreasing morbidity may therefore show more
persons dying in one year than developed the dis-
ease, particularly if the average survival time is
long.
Doll and Peto (5) have listed biases, or rather pos-
sible biases, in mortality and morbidity data (Table
2). While realizing that various diagnostic inaccura-
cies and errors may affect both sets of data, they
have overlooked that mortality data may be influ-
enced by overdiagnosis of cancer, and furthermore,
that the consequences of changes in definitions and
in the interest of physicians will not be restricted to
morbidity rates.
Mortality rates will tend to be reduced by suc-
cessful therapy, and morbidity data must be
checked for redundant reports of the same case,
which is not too difficult, but both systems will have
to live with the effects of the inclusion of early and
less malignant cases. For a cancer registry it is not
too difficult to evaluate the impact of a screening
program on morbidity data, and subsequently on
survival, but the effect on mortality numbers from
330CANCER EPIDEMIOLOGY
the elimination of an early carcinoma in situ may
not appear till ten or more years later. Hence the
apparent stability of mortality rates, which may
convey a false impression of reliability.
We shall therefore never be able to interprete
mortality rates without the assistance of cancer reg-
istration, which has been organized for such pur-
poses. If the use of death certificates for cancer re-
search should be taken seriously , no doubt the In-
ternational Agency for Research in Cancer (IARC)
would have used its affiliation with WHO to have
histological diagnoses introduced on the certificates
when available. Perhaps we may hope for an initia-
tive with the U.S. Congress supported by the au-
thority of Doll and Peto.
The need for improvements of some kind appears
from the recent analysis by Percy et al. (9), who
give the topmost deficit in cases reported on U.S.
death certificates at 43.8% for rectum cancer.
Although from personal experience I would hesi-
tate to share the confidence in cancer morbidity
rates from all kinds of medical systems appearing
from the first part of Doll and Peto's review, I
would still be more disinclined to subscribe to their
Table 2. Alleged biases in cancer registration
and their exclusion.
Bias
Difficulties to population estimate
Multiple recording of cases
Improvements in diagnostic standards
Improvements in physicians' interest
Changes in diagnostic definitions
Search for "lumps" (of low malignancy)
Biases in mortality data
Cases not recognized
Primary site unknown
Primary site misdiagnosed
Primary site miscertified
Cases cured
Cases misdiagnosed as cancer
Exclusion
Census
Linkage (number,
name, etc.)
Contact with
clinicians
Contact with
clinicians
Definitions
watched
Analysis of search
results and
of survival.
depreciation in the last part of morbidity data from
Connecticut and for upstate New York in favor of
the mortality rates for the United States with a
view to the evaluation of present-day epidemiology
I shall, therefore, show a comparison of rates from
the two old American registries with those from the
Danish, (Table 3), which dates from 1942 and is
about the same age (6-8,10-12).
Comparison of American and
Danish Registration Data
As an introduction of this hobby of mine, besides
clinical and pathology work, I show the percent of
cases admitted to a hospital and histologically ex-
amined for some neoplasms (Table 3) studied par-
ticularly by Doll and Peto, and in the following.
It appears that since 1950, more than 90% of pa-
tients have been admitted to a hospital, so that the
data are as good as from any other registry. The
same applies to histological verification.
Upstate New York
As the first bias of registration data, Doll and
Peto mention the difficulties involved in delimita-
tion of the population at risk. This might be ex-
pected to be particularly pronounced for a registry
serving the State of New York less New York City,
and to be nonexistent in Denmark. So, when we
found the absence in upstate New York of the in-
crease in testis cancer found in Denmark and in
Connecticut (13), this was our immediate explana-
tion, but we cannot be certain. There may be a real
difference in risk as between Denmark and Finland,
or between Quebec and Manitoba, since we have
not found other evidence of such differences due to
bias.
In fact, comparison of morbidity-age curves for
Copenhagen and upstate New York for 1950 (1) and
for 1970 (21) show practically identical age-curves
for Hodgkin's disease (Fig. 1). What is more the
same applies to leukemia, for which correspondence
extends to data specially collected from Brooklyn
by MacMahon and Clarke (14) as well as to multiple
myeloma (1). It does seem difficult from these obser-
Table 3. Cases in Copenhagen admitted to hospital and histologically verified cases (Danish Cancer Registry).
Stomach (m) Colon(m) Sigmoid(m) Rectum(m) Bladder(m) Prostate (m) Breast (f)
Hosp. Hist. Hosp. Hist. Hosp. Hist. Hosp. Hist. Hosp. Hist. Hosp. Hist. Hosp. Hist.
1943-47 86% 46% 89% 59% 91% 650/ 80% 79% 94% 75% 95% 69% 93% 88%
1948-52 89 64 90 70 92 83 96 83 97 80 95 72 96 88
1953-57 94 79 90 82 98 82 97 88 98 82 96 78 97 89
1958-62 93 81 95 85 98 90 98 91 93 83 95 76 98 91
1963-67 95 84 95 86 99 94 98 93 99 91 96 82 98 92
1968-72 97 90 99 89 100 93 99 93 99 95 96 86 98 92
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vations to accept a theory of a systematic bias on
population at risk.
Connecticut
In Connecticut fresh data on morbidity have been
collected since 1941, and in order to test the effect
of inclusion of premalignant cases on numbers, we
may turn to a comparison of data for the uterine
cancers with those from Copenhagen. It may be re-
called that at a time when English mortality data
had shown a social gradient for uterine cancer
deaths unfavorable to the poor, the highly specified
morbidity data for Copenhagen made it possible to
refer the gradient to differences in morbidity-not
to the effect of therapy-limited to cervical uterine
cancer (1). Nonspecified uterine cancers in Copen-
hagen (1943-47) amounted only to 3.8% against
25.8% for Connecticut, which only 25 years later at-
tained a corresponding coverage ofspecification.
Nevertheless, histology in Connecticut proved
the more efficient (Table 4). Cases of carcinoma in
situ of the cervix were collected in large numbers,
which resulted in continuous decrease in morbidity
from cervix carcinoma. In Copenhagen screening be-
gan only 20 years later, which allowed a rise in
rates, until screening turned it into a decrease (12).
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Besides showing how prevention of cancer may
spoil good statistics this combination of registration
Table 4. Comparison of Danish and
U.S. data on uterine cancers.
Histolog-
ically Rate
Cases, No. of cases verified, per 100,000 In
Years % Corpus Cervix 0o% (Europ. stand.) situ
Greater Copenhagen 1943-1972
1943-47 3.8 322 1113 95.5
1948-52 2.1 472 1192 97.5
1953-57 2.7 554 1352 94.9
1958-62 2.3 535 1321 96.7
1963-67 0.7 611 1356 97.2
1968-72 1.0 592 965 98.2
Connecticut Tumor Registry 1935-73
1935-39 29.3% 294 882
1940-44 25.8 388 902
1945-49 21.1 558 1046
1950-54 17.8 799 1059
1955-59 12.5 1124 1121
1960-64 7.0 1290 975
1965-69 4.1 1508 905
1970-73 2.3 1591 724
31.0
33.0
35.7
39.0
39.7
34.3
1
2
68
215
597
1203
1868
1827
aData from Danish Cancer Registry (1977).
bData from Connecticut Tumor Registry, reported by
Laskey et al. (22).
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FIGURE 1. Hodgkin's disease. Incidence rates at various ages for upstate New York and Cophenhagen around 1950 and around
1970.
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data reflects a complex situation in a way mortality
data could never do.
Cancer of the Bladder
Cancer of the urinary bladder has been suspected
of bias by the inclusion during later years of cases
previously taken as papillomas. Such cases, when
untreated, unvariably end as malignant and have
therefore always been included in Danish data,
which, without bias, offer a good opportunity to
check for its possible effects (Fig. 2).
The first increase in morbidity from bladder can-
cer was in fact, observed from Danish morbidity
data, and an immediate analysis of an interview
study by Lockwood (15) revealed an association with
smoking, although less than that found for lung can-
cer in most places. The influence of non-tobacco fac-
tors must vary considerably, since the ratio of lung
cancer to bladder tumors remains at ca. 2.8 in Den-
mark, Norway and Sweden, while English registries
reporting morbidity rates for lung about the same
as Copenhagen's show only half its rates for blad-
der, (2). A rough estimate of a ratio for the U.S. cal-
culated from mortality rates (16) was similar to Nor-
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way's but varied considerably among the states (17).
Logically, an absence of an increase in bladder
cancer rates for the United States would, if real, be
significant as a clue to tobacco carcinogenesis of the
bladder. In fact Doll and Peto, and before them De-
vesa and Silverman (18) referred to decreasing mor-
tality rates, despite a rise reported for morbidity.
Also in this case Doll and Peto accept mortality
rates as the more reliable indicator and ascribe the
discrepancy partly to inclusion in the data of an in-
creasing number of "papillomas." Nevertheless, in
Denmark where this does not apply, crude five-year
survival rates have risen from 23% about 1945 to
ca. 40% twenty years later with general survival
unchanged (12).
A comparison of the pattern of increase in blad-
der cancer morbidity for Copenhagen (Denmark),
and Connecticut shows approximately the same pat-
tern as a similar one in upstate New York (Fig. 3).
Once more, it is difficult to find place for a bias, and
an estimate of the avoidable amount of the bladder
cancer is difficult.
Also the numerical values of morbidity rates for
the three registries seem quite comparable (Table
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FIGURE 2. Bladder tumors (including papillomas). Incidence rates at various ages for birth group cohorts born around year in-
dicated, for males in all of Denmark and in Denmark's capital.
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5). It may be noted that age adjustment to the Euro-
pean Standard tends to increase American rates
more than it does the Danish.
For further evaluation of mortality versus mor-
bidity data, Doll and Peto have chosen cancers of
the female breast, the intestine and the prostate.
Breast Cancer
Breast cancer is increasing according to Devesa
and Silverman (18), and also in this case Connecticut
seems ahead of Copenhagen, while upstate New
York shows rates between those for the Danish cap-
ital and all of Denmark (Table 6, Fig. 4). Here again
an increase is ascribed to the inclusion of biologi-
cally less malignant "lumps" discovered by the
screening.
In Denmark a campaign for breast self-examina-
tion was begun in 1951, much on the American pat-
tern, planned and followed in collaboration with the
cancer registry. Numbers of fresh cases rose from
1082 in 1950 to 1407 in 1952, but dropped somewhat
again when the campaign ended, having brought
survival rate up to the U.S. level, where it remained
despite later attempts to improve it (1). It is inter-
esting that the 7-year survival rate for women un-
der 44 years of age improved, so that for the first
Table 5. Bladder tumors (males), morbidity per 100,000,
1940-1972.
Morbidity per 100,000
Upstate
Period Connecticut NY Denmark Copenhagen
1940-1944 11.4 - - -
1941-1943 - 10.6 - -
1943-1947 - - 8.7a, 6.4 13.8a
1945-1949 15.5 - - -
1949-1951 - 11.9 - -
1948-1952 - - 11.9a, 9.3 20.8a
1950-1954 17.2 - - -
1953-1957 - - 16.2a, 13.3 26.7a
1955-1959 20.3 - - -
1958-1960 - 16.1,20.3a - -
1960-1962 19.8, 25.3a - - _
1958-1962 - - 18.7a, 16.4 28.3a
1963-1965 29.9a
1963-1967 - - 24.1a, 22.2 37.5a
1968-1972 31.7a - 29.7a, 28.7 43.8a
1969-1971 - 25.1a - -
aAge-adjusted European standard.
FIGURE 3. Bladder cancer. Morbidity rates at various ages for birth cohorts for Connecticut and for upstate New York.
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time it exceeded the rate for older women, and it re-
mained in that position. The overall increase in mor-
bidity continued, however, and, therefore, cannot be
explained by discovery of benign lumps.
It should be noted that peaks on morbidity rate
curves, as seen for Connecticut, cannot be expected
to show in mortality data, until after average sur-
vival has expired, and then the spread of survival
time will tend to even them out.
For comparison, morbidity rates for smaller com-
munities are preferable to mortality data covering
populations of scores of millions with widely differ-
ent lifestyle.
Devesa and Silverman found that while gastric
cancer decreased in the U.S., morbidity of intestinal
cancer increased, while rectum cancer decreased in
morbidity (Table 7); this is exactly what happened in
Denmark. Also Connecticut and upstate New York
showed increases for intestinal cancer, but no clear
decrease for sigmoid and rectum cancer is visible in
Table 7, possibly due to the effect of the age adjust-
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FIGURE 4. Age-adjusted incidence
sites in females for Denmark, 1943-76.
1965 1975
for cancer of various
ment. Here again, the shortcomings of mortality
data are evident, since they vary considerably in
coverage for the various sites (9).
Prostate Cancer
Since 1935, prostatic cancer has been known to
be histologically demonstrable in many men without
symptoms, such as 14% between ages 41 and 50
years. It is particularly frequently reported among
the very old, and therefore the apparent increase in
morbidity has been followed with some reservation,
awaiting diagnoses of more clinical relevance.
Data for Connecticut and upstate New York show
a considerable effect from age adjustment to a
European Standard, and naturally Copenhagen less
so, and the difference between Connecticut and
Copenhagen rates seems to be increasing (Table 8).
However, it is difficult to see how mortality data
could provide better information, or how it should
be possible to estimate the avoidable amount of
cancer.
I am in full sympathy with the effort by Doll and
Peto to correct exaggerations of the increase in
morbidity from most cancers (cf. Fig. 5) by claims of
a cancer "epidemic." However, I should appeal to
their understanding of the views of the late William
Cramer (19, 20), whose advice I had the privilege of
taking in the late 1930s as a guest at the Imperial
Cancer Research Fund. With some pangs of con-
science I realize, that like Doll and Peto I have used
the term "theory" of Cramer's rule that the number
of persons susceptible to cancer seemed the same
everywhere. It seems to me somewhat overinter-
preted to read it that Cramer failed to realize that
the coefficient of variation of total cancer must of
Table 6. Breast cancer (females), morbidity per 100,000,
1940-1972.
Morbidity per 100,000
Upstate
Period Connecticut NY Denmark Copenhagen
1940-1944 55.3 - - -
1941-1943 - 56.4 - -
1943-1947 - - 59.4a 71.8a
1945-1949 59.7 - - -
1949-1951 - 55.0 - -
1948-1952 - - 61.2a 73.3a
1950-1954 64.7 - - -
1953-1957 - - 61.4a 71.1a
1955-1959 64.0 - - -
1958-1960 - 55.9, 67.9a - _
1960-1962 66.2,81.9a - - -
1958-1962 - - 63.6a 73.5a
1963-1965 85.3a _ _
1963-1967 - - 68.9a 79.5a
1968-1972 97.7a - 74.7a 83.3a
1969-1971 - 78.7a _ _
aAge-adjusted European standard.
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necessity be less than that of individual cancer
rates. However, I find consolation in the fact that
the same could be said of their comparison of cancer
morbidity rates for single states and mortality rates
for the U.S. population of some 200 million.
Future Requirements to Cancer
Epidemiology
Analysis of human data with regard to effects
from initiators and promoters will increase the de-
mands for accuracy of the time factors involved in
carcinogenesis.
Accurate information on periods of suspected ex-
posure should be made available as much as possi-
ble. Safekeeping of payrolls or similar information
should be provided for by chemical and related in-
dustries over four decades.
The demand for accuracy also applies to data for
the development of neoplasms, which means that
we need more accurate data on the duration of la-
Table 7. Cancer of colon and of sigmoid colon and rectum and total colon, morbidity per 100,000, 1940-1972.
Morbidity per 100,000
Period Site Connecticut Upstate NY Denmark Copenhagen
1940-1944 Colon
1941-1943
1943-1947
1945-1949
1949-1951
1948-1952
1950-1954
1953-1957
1955-1959
1958-1960
1960-1962
1958-1962
1963-1965
1963-1967
1968-1972
1969-1971
Sig-Rect
Total
Colon
Sig-Rect
Total
Colon
Sig-Rect
Total
Colon
Sig-Rect
Total
Colon
Sig-Rect
Total
Colon
Sig-Rect
Total
Colon
Sig-Rect
Total
Colon
Sig-Rect
Total
Colon
Sig-Rect
Total
Colon
Sig-Rect
Total
Colon
Sig-Rect
Total
Colon
Sig-Rect
Total
Colon
Sig-Rect
Total
Colon
Sig-Rect
Total
Colon
Sig-Rect
Total
Colon
Sig-Rect
Total
aAge-adjusted European standard.
22.6
17.6
40.2
24.7
20.1
44.7
27.0
20.7
47.7
30.2
19.3
49.5
29.2, 38.8a
17.1, 22.7a
46.3, 61.5a
40.5a
15.8a
57.3a
46.2a
27.2a
73.4a
16.6
13.8
30.4
19.7
15.5
35.2
22.7
15.3
38.1
37.7a
20.5a
58.2a
13.7a
38.0a
51.7a
13.3a
36.6a
49.9a
12.8a
33.5a
46.3a
13.6a
30.8a
50.4a
14.6a
36.3a
50.9a
15.5a
37.3a
52.8a
17.2a
47.9a
65.1a
17.0a
45.8a
62.8a
19.9a
41.6a
61.5a
18.3a
45.1a
63.4a
19.1a
44.8a
63.9a
22.7a
43.2a
67.9a
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tent periods for human tumors, and on the spread of
these values.
The definition of latent period varies from experi-
ments to human data, but for human data so many
factors may have played a part in their estimate in
the past, that the time has come for a critical reas-
sessment of data from the last 100 years, which
easily could be done by three scientists and a secre-
tary. Death certificates mentioning cancer should al-
ways state the histological diagnosis, if any.
With the necessary information (Fig. 6) we may
have to discard much old material, but we will be
able to plan the collection of the relevant data for
the estimate of the influence of initiators and
promotors.
Table 8. Prostatic carcinoma, morbidity per 100,000, 1940-1972.
Morbidity per 100,000
Upstate
Period Connecticut NY Denmark Copenhagen
1940-1944 26.7 - - -
1941-1943 - 21.4 - -
1943-1947 - - 18.2a 24.0a
1945-1949 29.0 - - -
1949-1951 - 24.9 - -
1948-1952 - - 23.7a 31.5a
1950-1954 34.8 - - -
1953-1957 - - 29.sa 37.3a
1955-1959 37.5 - - _
1958-1960 - 24.9, 39.1a - -
1960-1962 39.3, 55.2a - _ _
1958-1962 - - 32.6a 37.5a
1963-1965 54.0a - _ _
1963-1967 - - 36.4a 41.5a
1968-1972 61.4a - 37.2a 43.0a
1969-1971 - 48.3a _ _
aAge-adjusted European standard.
TRUE LATENT PERIOD
NUCLEAR EXPLOSION
I
I il l
itll
__ . .,
70
60
CO
z
uLJ
0
I-
C,)
0L
wD
50
40
30
20
10
0
1945 1955 1965 1975
YEAR
FIGURE 5. Age-adjusted incidence for cancer of various
sites in males for Denmark, 1943-76.
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FIGURE 6. Various concepts of latent periods in cancer.
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